Filing Details

Accession Number:
0001144204-13-052450
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-09-26 06:08:48
Reporting Period:
2013-09-24
Filing Date:
2013-09-26
Accepted Time:
2013-09-26 06:08:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
911148 Cadus Corp KDUS Biological Products, (No Disgnostic Substances) (2836) 133660391
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1377817 Moab Capital Partners Llc 152 East 62Nd Street
New York NY 10065
No No Yes No
1393832 Michael Rothenberg 152 East 62Nd Street
New York NY 10065
No No Yes No
1393833 Moab Gp Llc 152 East 62Nd Street
New York NY 10065
No No Yes No
1393834 Moab Partners Lp 152 East 62Nd Street
New York NY 10065
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2013-09-24 1,452,538 $1.45 0 No 4 S Indirect Performance related fees
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect Performance related fees
Footnotes
  1. The securities are owned directly by Moab Partners, L.P. (the "Fund"). Moab GP, LLC ("Moab GP"), the general partner of the Fund, and Moab Capital Partners, LLC ("Moab LLC"), the investment adviser to the Fund, each may be deemed to beneficially own the securities under Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act"). Michael M. Rothenberg is the Managing Member of Moab GP and Moab LLC and may also be deemed to beneficially own the securities under Section 13(d) of the Exchange Act. Moab LLC, Moab GP and Mr. Rothenberg disclaim beneficial ownership of the securities for purposes of Section 16 of the Exchange Act, except the extent of their pecuniary interest in the securities.